Skip to content
Science
Our Science
Autoimmunity
P140
Type M & Diagnostic
Type 1 Diabetes
Kapiglucagon
Anti-infectives
BioAMB
BioCIN
Pipeline
Company
Mission
About Us
Our Team
ImmuPharma Biotech
Investors
Investors
AIM Rule 26 Information
Regulatory News
Corporate Governance
Board of Directors
Annual Reports
Advisers
Email Alert
Updates
Announcements
Interviews
In the Media
Contact
Notification of Major Holding – Lanstead Capital
Oct 11, 2024
To view notification
click here
←
Previous:
Extension of Warrants in Incanthera to 31 March 2025
Next:
Appointment of Company Secretary
→
